menu
    • menu

    Company profile for Verismo Therapeutics

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (K...
    Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Verismo TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3675 Market Street, Suite 200 Philadelphia, PA 19104
    Telephone
    Telephone
    (215) 989-4225
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://verismotherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Verismo Therapeutics Unveils Superior SynKIR-310 KIR-CAR Data
    Verismo Therapeutics Unveils Superior SynKIR-310 KIR-CAR Data

    21 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/verismo-therapeutics-presents-preclinical-data-at-aacr-2026-for-synkir-310-kir-car-indicating-superior-preclinical-activity-in-b-cell-malignancies-and-early-clinical-efficacy-302748987.html

    PR NEWSWIRE
    21 Apr 2026
    Share Share
    Verismo Secures $28M from HLB to Accelerate KIR-CAR Trial
    Verismo Secures $28M from HLB to Accelerate KIR-CAR Trial

    15 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7181748

    FIRSTWORD PHARMA
    15 Apr 2026
    Share Share
    Verismo: Novel Multi-Chain SynKIR-110/-310 Initial Clinical Data
    Verismo: Novel Multi-Chain SynKIR-110/-310 Initial Clinical Data

    18 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/verismo-therapeutics-to-present-novel-multi-chain-kir-car-data---including-initial-clinical-trial-results-for-lead-immuno-oncology-candidates-synkir-110-and-synkir-310--at-aacr-annual-meeting-2026-302716606.html

    PR NEWSWIRE
    18 Mar 2026
    Share Share
    Verismo Treats First Follicular Lymphoma Patient in CELESTIAL-301
    Verismo Treats First Follicular Lymphoma Patient in CELESTIAL-301

    02 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/verismo-therapeutics-treats-first-follicular-lymphoma-patient-in-celestial-301-trial-strengthening-collaboration-with-ifli-302573330.html

    PR NEWSWIRE
    02 Oct 2025
    Share Share
    Verismo Pharma Partners Miltenyi Biotec For Clinical Program
    Verismo Pharma Partners Miltenyi Biotec For Clinical Program

    25 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/verismo-therapeutics-announces-partnership-with-miltenyi-biotec-to-support-advancing-clinical-programs-302566211.html

    PR NEWSWIRE
    25 Sep 2025
    Share Share
    Verismo Wins Best Workplace in Philadelphia for Third Year
    Verismo Wins Best Workplace in Philadelphia for Third Year

    29 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/verismo-therapeutics-named-one-of-philadelphia-business-journals-2025-best-places-to-work-for-third-consecutive-year-302515529.html

    PR NEWSWIRE
    29 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search